CD274 and neoplasm: Since not all tumor cells are, or become, PDL1+, the CD3xPDL1 BiTE is likely to be most useful in combination with other immunotherapies that have modest immune cell activation activity and do not have the capability of neutralizing PD1-mediated immune suppression.